Mod­er­na, Mer­ck un­veil three-year mid-stage da­ta for vac­cine-Keytru­da com­bo in melanoma, with PhI­II un­der­way

Mod­er­na and Mer­ck re­port­ed Thurs­day that their per­son­al­ized melanoma can­cer vac­cine plus Keytru­da ap­proach de­liv­ered “con­tin­ued im­prove­ment” in re­duc­ing risk of dis­ease re­cur­rence or death …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER